Abstract A058: Tumour-associated myeloid cells expressing IL-10R2/IL-22R1 as a potential biomarker for diagnosis and recurrence of pancreatic ductal adenocarcinoma

Abstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a poor prognosis, largely due to late diagnosis and limited treatment options. The immunosuppressive tumor microenvironment (TME) further exacerbates the situation, hindering the effectiveness of traditional therapies. This study investigates the potential of IL-10R2/IL-22R1 expressing immune cells as novel biomarkers for early PDAC detection and recurrence monitoring, offering a potential avenue for improved patient outcomes. The research revealed a significant increase in the number of IL-10R2/IL-22R1 expressing immune cells in the peripheral blood of PDAC patients compared to healthy controls. These cells were found to infiltrate PDAC tissue and exhibit immunosuppressive functions, contributing to the TME's suppression of the immune response. Further investigation using a mouse model of PDAC demonstrated that early tumor progression was accompanied by a rise in IL-10R2/IL-22R1 expressing immune cells in the blood, highlighting their potential role in tumor development. In post-pancreatectomy patients, the study observed that elevated levels of IL-10R2+ immune cells were associated with earlier recurrence compared to the currently employed biomarker, CA19-9. This finding suggests that IL-10R2/IL-22R1 expressing immune cells could serve as valuable tools for predicting PDAC recurrence and potentially improving treatment outcomes. This research provides compelling evidence for the potential of IL-10R2/IL-22R1 expressing immune cells as promising biomarkers for early PDAC diagnosis and recurrence monitoring. However, further research is crucial to comprehensively understand their generation, function, and clinical utility. Larger-scale studies are needed to validate these findings and translate them into practical clinical applications for improved patient care. Citation Format: Hyung Keun Lee, So Young Kim, Soo-Hyun Chung, Sung Ill Jang, Bongkun Choi, Ji-Eun Kim, Dohee Yoon, Areum Yeo, Hyun Goo Kang, Jusung Lee, Yoon Ha Choi, Joon Seong Park, Yoolim Sung, Jong Kyoung Kim, Eun-Ju Chang, Dong Ki Lee. Tumour-associated myeloid cells expressing IL-10R2/IL-22R1 as a potential biomarker for diagnosis and recurrence of pancreatic ductal adenocarcinoma [abstract]. In: Proceedings of the AACR Special Conference: Liquid Biopsy: From Discovery to Clinical Implementation; 2024 Nov 13-16; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2024;30(21_Suppl):Abstract nr A058.